Acute myeloid leukemia with NPM1 somatic mutations

Celgene Corporation

12.1 Mechanism of Action Enasidenib is a small molecule inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme. Enasidenib targets the mutant IDH2 ...

Kura Oncology, Inc.

Menin Inhibitor [EPC]

12.1 Mechanism of Action Ziftomenib is a menin inhibitor that blocks the interaction of menin and lysine [K]-specific methyltransferase 2A (KMT2A). Ac...

Astellas Pharma US, Inc.

12.1 Mechanism of Action Gilteritinib is a small molecule that inhibits multiple receptor tyrosine kinases, including FMS-like tyrosine kinase 3 (FLT3...

Novartis Pharmaceuticals Corporation

12.1 Mechanism of Action Asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion p...

Rigel Pharmaceuticals, Inc.

12.1 Mechanism of Action Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). In patients with AML, susceptible ID...

Servier Pharmaceuticals LLC

Isocitrate Dehydrogenase 1 Inhibitor [EPC]

12.1 Mechanism of Action Vorasidenib is a small molecule inhibitor that targets isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2) enzymes. In vitro, vo...